Key Stats for Centene Stock
- Current Price: $53.69
- Target Price (Mid): ~$85
- Street Target: ~$52
- Potential Total Return: ~59%
- Annualized IRR: ~11% / year
- Earnings Reaction: +8.90% (April 28, 2026)
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Managed care stocks spent most of 2025 pricing in disaster, and Centene (CNC) took the worst of it. Shares hit a max drawdown of 59.93% on August 6, 2025, per TIKR, as investors priced in simultaneous deterioration across Medicaid, Medicare, and the ACA Marketplace. Bulls argued the damage was cyclical. Bears argued it would take years to unwind. The question heading into April 28 was whether Centene’s turnaround had actually started.
On April 28, Centene reported Q1 2026 adjusted diluted EPS of $3.37, beating the consensus estimate of $2.13 by 57.91%, per TIKR. Revenue of $49.9 billion topped forecasts by 5.03%. CNC surged 8.90% on the day. Management raised full-year adjusted EPS guidance to greater than $3.40, up from the prior floor of greater than $3.00. CNC now trades above the Street’s mean price target of ~$52. The question is whether that is the ceiling or the floor.
Three Segments Moving in the Right Direction
The Q1 beat was not concentrated in one segment, which is what makes it credible.
Medicaid, Centene’s largest business, delivered a health benefits ratio (HBR, the share of premium revenue paid out in medical claims) of 93.1%, a 50 basis point improvement from Q1 2025 and the third consecutive quarter of improvement. CEO Sarah London attributed the progress to a cost management program built over 18 months, spanning utilization management, clinical program expansion, network optimization, and fraud detection.
CFO Drew Asher noted on the call that AI-enabled tools are running as an independent validation layer alongside traditional forecasting, identifying fraud and abnormal claims patterns earlier. “Behavioral health remains the largest driver of trend,” London said, “but we are beginning to see pockets of deceleration across this cohort, largely in line with our expectations.” For a business where the medical cost trend ran above 6% in 2025, deceleration in even one category matters.
Medicare delivered an HBR of 84.9%, ahead of plan, with both Medicare Advantage and the Part D prescription drug plan (PDP) contributing. The PDP business ended Q1 with just over 8.7 million members. Specialty drug trend came in below the forecast embedded in Centene’s own bids, giving management more confidence in the trajectory of that business for the year. For Medicare Advantage, the path to breakeven in 2027 remains intact. D-SNP (Dual Eligible Special Needs Plan) membership is now at 40% of the Medicare Advantage portfolio, aligning the business more tightly with Centene’s core Medicaid competency.
The Commercial segment came in line on a pretax margin basis. A slightly higher Silver-tier HBR was offset by SG&A outperformance. That Silver-tier dynamic, however, is the most important unresolved variable in the 2026 story.
See historical and forward estimates for Centene stock (It’s free!) >>>
The ACA Risk Adjustment Thesis: Conservative Guidance, Real Upside
When enhanced ACA premium tax credits expired at the end of 2025, healthier enrollees left the Marketplace and remaining members shifted toward lower-cost Bronze plans. The Silver tier shrank and became more medically acute, because sicker members benefit most from Silver’s cost-sharing structure and were more likely to stay.
Centene did not chase Bronze aggressively. That left the company holding a higher-acuity Silver membership base, which drove higher gross medical costs in Q1 than originally forecast. That sounds like a problem, but the ACA’s risk adjustment mechanism is built for this scenario. “In other insurance markets, the concept of adverse selection can be scary,” London said on the call, “but that’s not actually the case in Marketplace, because the risk adjustment mechanism is specifically designed to counteract adverse selection.”
Centene now expects a slight risk adjustment receivable for the full year, a reversal from the net payable assumption in the original guidance. The March report from Wakely Consulting Group, the independent actuarial firm that calculates interim risk transfer estimates for the ACA market, confirmed that 75% of Centene’s Silver tier consisted of renewals, and that risk scores tracked in line with claims experience through Q1.
Asher told analysts the range of outcomes the current data supports wraps around Centene’s original 4% Marketplace pretax margin target, “and frankly, higher than that at the top end.” Management embedded a conservative ~3% pretax Marketplace margin in the updated guidance, leaving the upside for the June Wakely data to confirm.
See how Centene performs against its peers in TIKR (It’s free!) >>>
The 2027 Policy Risk
The harder conversation for Centene investors is 2027. The One Big Beautiful Bill Act (OBBB), signed into law on July 4, 2025, requires states to implement Medicaid work requirements for ACA expansion adults by January 1, 2027. Under the law, most non-exempt adults aged 19 to 64 must document at least 80 hours per month of qualifying community engagement activities to keep coverage. According to KFF, this provision accounts for the largest share of federal Medicaid savings in the OBBB. With roughly 12.4 million Medicaid members, Centene carries the most direct exposure to enrollment contraction of any single managed care insurer.
London’s response on the Q1 call was specific. She described state partners already running frailty analyses on their expansion populations, identifying at-risk pools smaller than broad estimates assumed. She also noted that CMS guidance explicitly requires states to factor work requirements into rate certifications, creating a framework for mid-year rate adjustments where material program changes occur.
Centene’s Health Net subsidiary committed $1 million in April 2026 to a public education campaign preparing California’s Medi-Cal members for the January 2027 requirements, per a company press release, a sign that management is treating this as an operational challenge to manage rather than a policy cliff to wait out. “We look at 2027 and 2028 as something that we feel confident that we can manage through,” London said.
The risk remains: enrollment losses that outpace rate adjustments would slow the margin recovery story. The offsetting view is Centene’s scale, its 29-state data advantage, and its entrenched state relationships.
TIKR Advanced Model Analysis
- Current Price: $53.69
- Target Price (Mid): ~$85
- Potential Total Return: ~59%
- Annualized IRR: ~11% / year
See analysts’ growth forecasts and price targets for Centene stock (It’s free!) >>>
The TIKR mid-case model targets ~$85 by December 31, 2030, using a mid-case revenue CAGR of around 4% and a net income margin recovery toward around 1%, consistent with the sequential progress Centene has already confirmed. The two revenue growth drivers are Medicaid premium yield expansion, where management is guiding a composite rate yield of around 4.5% in 2026, and PDP membership growth supporting Medicare segment revenue, which reached $37.2 billion in full-year 2025 per TIKR. The primary risk is the 2027 policy transition. If Medicaid enrollment losses outpace rate adjustments, the mid-case assumptions become optimistic.
The balance sheet improved materially in Q1: Centene retired $1 billion in senior notes by selling 2025 Part D risk share receivables, bringing debt-to-cap to 43.2% from 46.5% at year-end. Asher noted $1.2 billion in maturities due December 2027 and $2.3 billion due in the summer of 2028, which the company expects to refinance in advance. The free cash flow picture reflects the recovery trajectory: LTM FCF stands at $6.85 billion, 2026E FCF normalizes to around $1.34 billion as working capital resets, and consensus estimates project recovery toward around $2.4 billion by 2028, per TIKR.
The Street remains cautious. With 5 Buys, 2 Outperforms, 12 Holds, 1 Underperform, and 1 Sell, and a mean target of ~$52 already below the current price, the consensus reflects a wait-and-see posture ahead of the June Wakely data and the Q2 2026 print.
Conclusion
Watch the Medicaid HBR at the Q2 2026 earnings call on July 28, 2026. If it prints at or below 93.7% and the June Wakely data confirms a risk adjustment receivable above the 3% Marketplace margin embedded in current guidance, both of Centene’s biggest open questions resolve in the same window.
Centene’s Q1 2026 print is the strongest evidence yet that 2025 was a cost cycle and a risk adjustment dislocation, not a structural break in the business.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Centene?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Centene, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Centene alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Centene on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
